TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23419384
Drug: Gut-directed hypnotherapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut-directed hypnotherapy (GHT) with supportive talks and medical treatment (SMT)
Study: 23419384
Drug: Supportive talks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive talks with medical treatment (SMT)
Study: 14758818
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (809 nm‐GaAlAs‐laser, 50 mW, 150 s)
Study: 14758818
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (simulated laser treatment)
Study: 11355044
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with conjugated estrogens (0.625 mg/day) and medroxyprogesterone (2.5 mg/day) for 12 months
Study: 9207871
Drug: Ibuprofen-arginine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-arginine (400 mg orally, 90 min before surgery, 2 h after surgery, then every 8 h for 32 hours)
Study: 9207871
Drug: Placebo (doubled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (doubled blind, same timing as ibuprofen-arginine)
Study: 9207871
Drug: Ibuprofen-arginine and
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen-arginine and Placebo
Study: 7953427
Drug: 0.2 per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 per cent glyceryl trinitrate ointment
Study: 3591249
Drug: 1.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/kg of 0.5% bupivacaine injected for the block (Group 1)
Study: 3591249
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 0.25 mg/kg/h infusion (Group 2)
Study: 3591249
Drug: 1.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/kg of 0.5% bupivacaine (Group 1)
Study: 28287913
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill intervention
Study: 24233772
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple anti‐H. pylori therapy plus probiotics of L. acidophilus and B. bifidum for 2 weeks followed by taking probiotics for another 4 weeks
Study: 24233772
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple anti‐H. pylori therapy for 6 weeks
Study: 24233772
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple anti‐H. pylori therapy plus probiotics of L. acidophilus and B. bifidum
Study: 20339787
Drug: Topical heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical heparin treatment (group TH)
Study: 17899018
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine
Study: 16087981
Drug: Valine intake
Normalized name: Valine
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valine intake of 17 mg x kg(‐1) x d(‐1)
Study: 16087981
Drug: Valine intakes
Normalized name: Valine
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valine intakes of 5, 10, 15, 20, 25, 30, and 35 mg x kg(‐1) x d(‐1)
Study: 16087981
Drug: Leucine intake
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine intake maintained at 40 mg x kg(‐1) x d(‐1)
Study: 10332195
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adriamycin (ADM) + vincristine (VCR) + cyclophosphamide (CPM) + mitoxantrone + L-asparaginase
Study: 10332195
Drug: Attenuated induction
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated induction therapy for patients aged 75 or over
Study: 10332195
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction therapy for patients aged less than 75
Study: 8942334
Drug: Edrophonium (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (0.75 mg kg‐1)
Study: 8942334
Drug: Pyridostigmine (0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (0.24 mg kg‐1)
Study: 8942334
Drug: Neostigmine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.05 mg kg‐1)
Study: 3936186
Drug: Cost-sharing for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-sharing for drugs
Study: 25222757
Drug: High insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin with essential amino acids (EAAs)
Study: 25222757
Drug: Low insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low insulin with EAAs
Study: 25222757
Drug: Low insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low insulin
Study: 25222757
Drug: High insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin
Study: 25222757
Drug: EAA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EAA infusion
Study: 23229963
Drug: Focus on
Normalized name: Menthol 2.1 g in 60 mL TOPICAL GEL [Biocool Focus On]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focus on Medicines (FOM) program
Study: 15857930
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) therapy, administered as three monthly infusions.
Study: 11490530
Drug: 32P followed
Normalized name: Sodium phosphate (32P)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 32P followed by low-dose hydroxyurea (HU) maintenance therapy
Study: 8017870
Drug: 4-aminopyridine (AP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (AP), oral treatment for 3 months
Study: 2849011
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Angiotensin II and Vasopressin with CRF41 (100 micrograms)
Study: 26529074
Drug: Self-administered intradermal
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intradermal influenza vaccine (Intanza(®))
Study: 26529074
Drug: Nurse-administered intramuscular
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered intramuscular vaccine (Vaxigrip(®))
Study: 26529074
Drug: Nurse-led group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led group sessions for self-administration
Study: 23789889
Drug: Sensor-augmented insulin-pump
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin-pump therapy with threshold-suspend feature
Study: 23789889
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard sensor-augmented insulin-pump therapy)
Study: 21552138
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri 1×10 colony-forming units twice daily for 4 weeks
Study: 10933353
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus 20 mg/day simvastatin
Study: 11831346
Drug: Passive jaw
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive jaw motion device therapy (Therabite)
Study: 11831346
Drug: Wooden tongue
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wooden tongue depressors therapy (WTD)
Study: 7741566
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler (MDI) with a valved holding chamber
Study: 2048819
Drug: Budesonide, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, 800 micrograms twice a day
Study: 7002706
Drug: Loperamide (4.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (4.6 mg, 2.3 capsules)
Study: 7002706
Drug: Codeine (103.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (103.5 mg, 2.3 capsules)
Study: 7002706
Drug: Diphenoxylate (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenoxylate (12.5 mg, 2.5 capsules)
Study: 28746324
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (CBT and pharmacotherapy)
Study: 21259026
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise (AR: A + R)
Study: 19275979
Drug: Internet administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet administration of the Kansas City Cardiomyopathy Questionnaire (KCCQ)
Study: 19275979
Drug: Internet administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet administration of the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Study: 19275979
Drug: Internet administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet administration of the Self-Care Heart Failure Index (SCHFI)
Study: 19275979
Drug: Pen-and-paper administration
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pen-and-paper administration of the Kansas City Cardiomyopathy Questionnaire (KCCQ)
Study: 19275979
Drug: Pen-and-paper administration
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pen-and-paper administration of the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Study: 19275979
Drug: Pen-and-paper administration
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pen-and-paper administration of the Self-Care Heart Failure Index (SCHFI)
Study: 11332151
Drug: CEF14 (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF14 (chemotherapy regimen delivered every two weeks)
Study: 11332151
Drug: CEF21 (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF21 (chemotherapy regimen delivered every three weeks)
Study: 11332151
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of RT and CT
Study: 8424300
Drug: Clonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3 mg orally)
Study: 8424300
Drug: Lignocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (1.5 mg.kg‐1 prior to induction)
Study: 28591942
Drug: Sialidase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sialidase inhibitor N‐Acetyl‐2, 3‐dehydro‐2‐deoxyneuraminic acid (DANA)
Study: 22383336
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR (both doses)
Study: 18801190
Drug: Standardized hypnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized hypnosis treatment with ten consecutive therapeutic sessions once a week, each lasting about 30 minutes, focusing on ego-strengthening, relaxation, releasing muscular tension, and increasing self-efficacy.
Study: 18801190
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment during initial phase).
Study: 12717603
Drug: Subcutaneous specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous specific immunotherapy with Der p/Der f
Study: 2018441
Drug: Stanozolol 5
Normalized name: stanozolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanozolol 5 mg twice daily for 6 months
Study: 2018441
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily for 6 months
Study: 7114130
Drug: Progesterone implants
Normalized name: estradiol / progesterone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone implants (6 pellets of 100 mg each)
Study: 9738562
Drug: Raltitrexed (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed (3 mg/m2) once every 3 weeks
Study: 9738562
Drug: 5-FU (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (400 mg/m2) plus LV (200 mg/m2) daily for 5 days every 4 weeks
Study: 7972979
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg b.i.d. (sustained release tablets)
Study: 2743632
Drug: Daily observed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily observed prophylaxis (DOP) and education
Study: 2743632
Drug: Self‐administered anti‐tuberculous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered anti‐tuberculous prophylaxis (SAP) and education
Study: 4851604
Drug: Amiloride 10
Normalized name: amiloride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 10 mg daily in the postoperative period
Study: 29459184
Drug: Urinary cadmium
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary cadmium at 10 years (highest tertile: 0.30-2.6 μg/L)
Study: 22698919
Drug: 3.0 pmol/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 pmol/kg/min human BNP-32 administered as a continuous infusion during 4 h
Study: 18662627
Drug: Fast-track group
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-track group (FTG) with remifentanil and spinal analgesia (low-dose morphine and clonidine)
Study: 1869800
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg aspirin per day for two days
Study: 29183698
Drug: Customized porous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized porous titanium implants
Study: 29183698
Drug: Customized PEEK
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized PEEK implants
Study: 20166160
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) treatment on one side of the face, four treatments at 3- to 4-week intervals.
Study: 16314784
Drug: Tacrolimus plus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus plus low-dose short-term steroids
Study: 11923325
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of ramoplanin
Study: 11923325
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ramoplanin
Study: 11923325
Drug: Ramoplanin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramoplanin (all doses)
Study: 11923325
Drug: Ramoplanin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramoplanin (all doses) with antibiotics against anaerobic organisms
Study: 11923325
Drug: Ramoplanin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramoplanin (all doses) avoiding antibiotics against anaerobic organisms
Study: 1977079
Drug: Standard-treatment group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-treatment group (zidovudine 250 mg every four hours)
Study: 1977079
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (zidovudine 200 mg every four hours for four weeks, then 100 mg every four hours)
Study: 28697497
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of aflibercept (IVA) 2.0 mg every 2 months after 3 initial monthly doses
Study: 16926252
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) administration in men
Study: 16926252
Drug: Testosterone plus
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone plus GH administration in men
Study: 16926252
Drug: Sex steroid(s)
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex steroid(s) alone in women (estrogen/progesterone)
Study: 16926252
Drug: Sex steroid(s)
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex steroid(s) combined with GH in women
Study: 14741071
Drug: nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide 120 mg t.i.d. for 5 days
Study: 9107259
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of at least two drugs
Study: 9107259
Drug: Substitution or
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitution or addition of at least two new agents
Study: 9107259
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of two nucleoside analogues plus a third agent
Study: 9107259
Drug: Two protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two protease inhibitors
Study: 3004189
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet (500 mg cholesterol/day)
Study: 3004189
Drug: Low-cholesterol diet
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-cholesterol diet (250 mg/day)
Study: 3004189
Drug: Added-bran diet
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Added-bran diet (30 g/day)
Study: 31952982
Drug: Urate-lowering therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urate-lowering therapy (ULT) with Allopurinol
Study: 31952982
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment of asymptomatic and non-severe hyperuricemia
Study: 27141626
Drug: Forearm-injection (forearm-)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forearm-injection (forearm-)
Study: 27141626
Drug: Jiaji (EX-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiaji (EX-B 2)-injection (EX-B 2-1)
Study: 27141626
Drug: Zusanli-injection (ST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zusanli-injection (ST 36-1)
Study: 2941929
Drug: 2.5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 micrograms recombinant hepatitis B vaccine
Study: 31541597
Drug: Intradermal PRP
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal PRP injection and excimer laser
Study: 29738424
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol tablet (10μg)
Study: 27238895
Drug: Probiotic therapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic therapy along with NSAIDs for 12 weeks
Study: 16483967
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy in aCL positive primiparae (49 subjects)
Study: 14587042
Drug: Intermittent anti-D
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent anti-D treatment
Study: 14587042
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care (glucocorticoid treatment followed by splenectomy)
Study: 29217387
Drug: Standard duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard duration of elastic compression therapy (24 months)
Study: 27099242
Drug: Topical local
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical local anaesthesia
Study: 27099242
Drug: Water-based gel
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based gel (placebo)
Study: 25897826
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus rmhTNF (265 patients)
Study: 25897826
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (264 patients)
Study: 11823767
Drug: Paroxetine initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine initiation at 20 mg/d for 1 month
Study: 11823767
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment continued for at least 1 month
Study: 11823767
Drug: Any antipanic
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antipanic medication at 3 months
Study: 10782562
Drug: Atorvastatin (generally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (generally 10 mg/day)
Study: 8746920
Drug: Buprenorphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (2 mg daily)
Study: 8746920
Drug: Buprenorphine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (8 mg daily)
Study: 23666554
Drug: Trifluoromethylphenylpiperazine (TFMPP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluoromethylphenylpiperazine (TFMPP) 50 or 60 mg
Study: 23666554
Drug: Benzylpiperazine (BZP)
Normalized name: cinnamido benzylpiperidinyl ethoxypropylbenzamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpiperazine (BZP) 200 mg + Trifluoromethylphenylpiperazine (TFMPP) 100 mg + 30 mg
Study: 21489843
Drug: Group intervention
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group intervention comprising seminars only (group G; n=26)
Study: 21489843
Drug: Group intervention
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group intervention (group G)
Study: 19681868
Drug: Avizafone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avizafone (20 mg)
Study: 19681868
Drug: Diazepam (11.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (11.3 mg)
Study: 19681868
Drug: Avizafone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avizafone (20 mg) with atropine (2 mg) and pralidoxime (350 mg)
Study: 11720430
Drug: GM-CSF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF with dacarbazine (5 microg kg(‐1), bid, day 2 to day 19 every 21 days and DTIC: 800 mg m(‐2), day 1 of each cycle)